GlassScriptPhysician profile
Steve L Corder
NPI 1184726804
$57,201.39
in general payments reported to CMS, 2019-2025
22 companies · $10K in 2025
The $10K reported for 2025 was more than what 96% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,294 · 2020: $8,470 · 2021: $8,812 · 2022: $2,044 · 2023: $2,048 · 2024: $17K · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Food and Beverage: $7,715 · Travel and Lodging: $2,293 · Consulting Fee: $730 · Education: $254.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,590.50 |
| Food and Beverage | $7,715.14 |
| Travel and Lodging | $2,292.54 |
| Consulting Fee | $730.00 |
| Education | $253.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $45,378.02 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Abbvie INC. | $1,875.03 | 2021-2025 | Vraylar |
| Vanda Pharmaceuticals INC. | $1,579.83 | 2019-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $1,558.42 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Neurocrine Biosciences, INC. | $1,505.29 | 2019-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $1,009.16 | 2019-2025 | Invega, Spravato |
| Otsuka America Pharmaceutical, INC. | $957.09 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $835.92 | 2020-2025 | Caplyta |
| Indivior INC. | $472.02 | 2022-2025 | Sublocade |
| Sunovion Pharmaceuticals INC. | $421.36 | 2019-2021 | |
| Janssen Scientific Affairs, LLC | $400.00 | 2024-2025 | Spravato |
| Lundbeck LLC | $302.05 | 2020-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $264.56 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $169.11 | 2023-2025 | Auvelity |
| Avanir Pharmaceuticals, INC. | $137.18 | 2019-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $95.63 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $80.68 | 2021 | |
| Allergan, INC. | $70.30 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $39.99 | 2020-2021 | |
| Braeburn INC. | $17.77 | 2025 | Brixadi |
| Acadia Pharmaceuticals INC | $17.15 | 2020 | |
| Sage Therapeutics, LLC | $14.83 | 2025 | Zurzuvae |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steve Corder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.